J.Safra Asset Management Corp Buys 59 Shares of argenx SE (NASDAQ:ARGX)

J.Safra Asset Management Corp increased its position in argenx SE (NASDAQ:ARGX) by 590.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69 shares of the company’s stock after purchasing an additional 59 shares during the period. J.Safra Asset Management Corp’s holdings in argenx were worth $30,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ARGX. GAMMA Investing LLC boosted its stake in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after purchasing an additional 63 shares during the last quarter. Mather Group LLC. bought a new stake in argenx in the 1st quarter worth about $38,000. Benjamin F. Edwards & Company Inc. purchased a new position in argenx in the 4th quarter worth about $60,000. Lindbrook Capital LLC lifted its stake in argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after acquiring an additional 37 shares during the period. Finally, Principal Securities Inc. purchased a new stake in shares of argenx during the 4th quarter valued at about $99,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Robert W. Baird increased their price objective on shares of argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Evercore ISI increased their price target on argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a report on Friday, July 12th. Oppenheimer raised argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price objective for the company in a report on Tuesday, July 23rd. Wells Fargo & Company upped their target price on shares of argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a report on Friday, July 26th. Finally, Bank of America restated a “buy” rating and issued a $607.00 price target (up previously from $535.00) on shares of argenx in a research report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average target price of $540.37.

argenx Price Performance

Shares of NASDAQ:ARGX traded down $0.42 during trading hours on Friday, hitting $524.48. The company’s stock had a trading volume of 28,212 shares, compared to its average volume of 329,509. The firm’s fifty day moving average price is $455.69 and its 200 day moving average price is $408.20. argenx SE has a 52 week low of $327.73 and a 52 week high of $540.49. The company has a market capitalization of $31.17 billion, a price-to-earnings ratio of -92.74 and a beta of 0.64.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The company had revenue of $489.43 million during the quarter, compared to analyst estimates of $436.66 million. During the same quarter in the prior year, the business earned ($1.69) earnings per share. On average, equities research analysts predict that argenx SE will post -0.48 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.